J F Deeken

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi The Affymetrix DMET platform and pharmacogenetics in drug development
    John Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Curr Opin Mol Ther 11:260-8. 2009
  2. ncbi Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Mol Pharmacol 76:946-56. 2009
  3. ncbi The blood-brain barrier and cancer: transporters, treatment, and Trojan horses
    John F Deeken
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 13:1663-74. 2007
  4. ncbi Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia 20007, USA
    Cancer 113:1502-10. 2008
  5. ncbi Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Curr Opin Oncol 21:445-54. 2009
  6. ncbi A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform
    J F Deeken
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Pharmacogenomics J 10:191-9. 2010
  7. ncbi Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer
    Keith R Unger
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC 20007, USA
    Int J Radiat Oncol Biol Phys 77:1411-9. 2010
  8. ncbi Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2113, USA
    Clin Cancer Res 16:4038-45. 2010
  9. ncbi Cetuximab in the treatment of rheumatoid arthritis
    Timothy Sullivan
    Department of Internal Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
    J Clin Rheumatol 16:32-3. 2010
  10. ncbi Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics
    John F Deeken
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20895, USA
    Anticancer Drugs 18:111-26. 2007

Collaborators

Detail Information

Publications10

  1. ncbi The Affymetrix DMET platform and pharmacogenetics in drug development
    John Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Curr Opin Mol Ther 11:260-8. 2009
    ..Future clinical research that incorporates comprehensive genotyping platforms should greatly advance our knowledge of the pharmacogenetics of drug disposition, improve drug development, and usher in the era of personalized medicine...
  2. ncbi Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Mol Pharmacol 76:946-56. 2009
    ..In summary, COMPARE analysis of the NCI drug screen database using the ABCG2 functional profile was able to identify novel substrates and transporter-interacting compounds...
  3. ncbi The blood-brain barrier and cancer: transporters, treatment, and Trojan horses
    John F Deeken
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Clin Cancer Res 13:1663-74. 2007
    ..Finally, strategies to overcome this barrier and better deliver chemotherapy into CNS tumors are presented...
  4. ncbi Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia 20007, USA
    Cancer 113:1502-10. 2008
    ..Consequently, these test results are supplementary to clinical judgment, which requires assessing multiple variables that contribute to phenotype to arrive at individual dosing decisions...
  5. ncbi Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook
    John F Deeken
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Curr Opin Oncol 21:445-54. 2009
    ..Treating non-AIDS-defining cancers in patients who are on highly active antiretroviral therapy is an open and complicated clinical question...
  6. ncbi A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform
    J F Deeken
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20007, USA
    Pharmacogenomics J 10:191-9. 2010
    ..These findings highlight the role that non-CYP450 metabolizing enzymes and transporters may have in the pharmacology of docetaxel and thalidomide...
  7. ncbi Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer
    Keith R Unger
    Department of Radiation Medicine, Georgetown University Hospital, Washington, DC 20007, USA
    Int J Radiat Oncol Biol Phys 77:1411-9. 2010
    ..We report our experience with reirradiation using fractionated SRS for head-and-neck cancer...
  8. ncbi Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma
    Jimmy J Hwang
    Lombardi Cancer Center, Georgetown Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2113, USA
    Clin Cancer Res 16:4038-45. 2010
    ..The two studies, GX001 and GX005, evaluated the safety and tolerability of weekly 1-hour and 3-hour infusions of obatoclax, respectively...
  9. ncbi Cetuximab in the treatment of rheumatoid arthritis
    Timothy Sullivan
    Department of Internal Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
    J Clin Rheumatol 16:32-3. 2010
    ..The case as well as possible mechanisms of action are discussed. Further clinical investigations are clearly warranted...
  10. ncbi Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics
    John F Deeken
    Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20895, USA
    Anticancer Drugs 18:111-26. 2007
    ..Several of these genotyping strategies have been shown to have substantial impact on therapeutic outcome and should eventually lead to improved anticancer chemotherapy...